{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:04:40Z","timestamp":1747181080878,"version":"3.40.5"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"49","license":[{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,9]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Glioblastoma is the most common malignant tumor of the central nervous system, which originates from glial cells and corresponding precursors. Due to its strong invasion and rapid growth, the prognosis of patients after treatment is very poor and easy to relapse.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>In August 2015, a 48 years old man with a relapse of glioblastoma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>The patient was diagnosed by computed tomography, magnetic resonance imaging, and pathological biopsy in this case report.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The patient underwent 2 surgeries, radiotherapy, and multiple regular chemotherapy sessions over the next 6 years. Apatinib, an inhibitor of vascular endothelial growth factor receptor 2 was given to treat recurrent glioma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>It was found that radiotherapy combined with temozolomide administration often increased the size of the original lesion or produced a new glioblastoma lesion. The lesion development was similar to tumor progression, which was called pseudoprogression. And it significantly prolonged the survival of this patient.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Surgery, radiotherapy and chemotherapy with apatinib and temozolomide are effective to treat the patients with pseudoprogression in glioblastoma.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000032156","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T21:27:56Z","timestamp":1673558876000},"page":"e32156","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Apatinib combined with temozolomide treatment for pseudoprogression in glioblastoma: A case report"],"prefix":"10.1097","volume":"101","author":[{"given":"Mingming","family":"Zhao","sequence":"first","affiliation":[{"name":"First Ward of Cancer Center, People\u2019s Hospital of Henan University, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haodong","family":"Ma","sequence":"additional","affiliation":[{"name":"First Ward of Cancer Center, Henan Provincial People\u2019s Hospital, Zhengzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Cheng","sequence":"additional","affiliation":[{"name":"First Ward of Cancer Center, Henan Provincial People\u2019s Hospital, Zhengzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongjie","family":"Yang","sequence":"additional","affiliation":[{"name":"First Ward of Cancer Center, Henan Provincial People\u2019s Hospital, Zhengzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Zhao","sequence":"additional","affiliation":[{"name":"First Ward of Cancer Center, Henan Provincial People\u2019s Hospital, Zhengzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3784-1033","authenticated-orcid":false,"given":"Qian","family":"Han","sequence":"additional","affiliation":[{"name":"First Ward of Cancer Center, Henan Provincial People\u2019s Hospital, Zhengzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11060-008-9718-y","article-title":"Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan","volume":"91","author":"Zuniga","year":"2009","journal-title":"J Neurooncol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"key":"R3-20250504","first-page":"744","article-title":"Glioblastoma-treatment and obstacles","volume":"27","author":"Cantidio","year":"2022","journal-title":"Rep Pract Oncol Radiother"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12880-020-00545-5","article-title":"Differentiation of pseudoprogression from true progressionin glioblastoma patients after standard treatment: a machine learning strategy combinedwith radiomics features from T1-weighted contrast-enhanced imaging","volume":"21","author":"Sun","year":"2021","journal-title":"BMC Med Imaging"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3390\/biomedicines10020285","article-title":"Pseudoprogression in glioblastoma: role of metabolic and functional MRI-systematic review","volume":"10","author":"Sidibe","year":"2022","journal-title":"Biomedicines"},{"key":"R6-20250504","first-page":"1204","article-title":"Antitumor activity of Cedrelone in temozolomide-resistant human glioma cells is accompanied by mitochondrial mediated apoptosis, inhibition of angiogenesis, cell cycle disruption and modulation of ERK\/MAPK signalling pathway","volume":"24","author":"Cao","year":"2019","journal-title":"J BUON"},{"key":"R7-20250504","first-page":"2465","article-title":"3175 and miR-134 affect proliferation, invasion and apoptosis of glioma cells through PI3K\/AKT signaling pathway","volume":"24","author":"Qi","year":"2019","journal-title":"J BUON"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"109445","DOI":"10.1016\/j.ejrad.2020.109445","article-title":"Differentiating high-grade glioma recurrence from pseudoprogression: comparing diffusion kurtosis imaging and diffusion tensor imaging","volume":"135","author":"Wu","year":"2021","journal-title":"Eur J Radiol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(14)70314-6","article-title":"Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial","volume":"15","author":"Taal","year":"2014","journal-title":"Lancet Oncol"},{"key":"R10-20250504","first-page":"3","article-title":"Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment","volume":"18","author":"Hanif","year":"2017","journal-title":"Asian Pac J Cancer Prev"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.rcl.2019.07.003","article-title":"Imaging glioblastoma posttreatment: progression, pseudoprogression, pseudoresponse, radiation necrosis","volume":"57","author":"Strauss","year":"2019","journal-title":"Radiol Clin North Am"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"6828396","DOI":"10.1155\/2018\/6828396","article-title":"Irradiation necrosis, pseudoprogression, pseudoresponse, and tumor recurrence: imaging challenges for the evaluation of treated gliomas","volume":"2018","author":"Zikou","year":"2018","journal-title":"Contrast Media Mol Imaging"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.clineuro.2016.10.004","article-title":"IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy","volume":"151","author":"Li","year":"2016","journal-title":"Clin Neurol Neurosurg"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/neuonc\/noy133","article-title":"Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improves diagnostic performance for pseudoprogression in glioblastoma patients","volume":"21","author":"Kim","year":"2019","journal-title":"Neuro Oncol"},{"key":"R15-20250504","first-page":"209","article-title":"The role of VEGF in the regulation of physiological and pathological angiogenesis","author":"Ferrara","year":"2005","journal-title":"Exs"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.bcp.2011.12.007","article-title":"Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells","volume":"83","author":"Tong","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"7981","DOI":"10.1158\/0008-5472.CAN-10-0111","article-title":"Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters","volume":"70","author":"Mi","year":"2010","journal-title":"Cancer Res"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"601175","DOI":"10.3389\/fonc.2020.601175","article-title":"Apatinib plus temozolomide: an effective salvage treatment for recurrent glioblastoma","volume":"10","author":"Ge","year":"2021","journal-title":"Front Oncol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/j.ejca.2012.04.011","article-title":"NovoTTF-100A versus physician\u2019s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel randomised phase III trial of a novel treatment modality","volume":"48","author":"Stupp","year":"2012","journal-title":"Eur J Cancer"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032156","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:48:42Z","timestamp":1746334122000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":19,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032156","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2022,12,9]]}}}